NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

10836	Companies
235277	Keywords
164215	Articles
126032	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 12/17/2024 at 22:15, 1 year 7 months ago

NANOBIOTIX présentera sa vision pour révolutionner la conception et le développement de médicaments à travers sa prochaine plateforme nanothérapeutique le 19 décembre 2024
Nanobiotix présente sa plateforme nanothérapeutique lors d'un événement virtuel le 19/12 à 15h00 CET / 9h00 ET pour améliorer les traitements pour les patients atteints de cancer

Innovation Cancer Événement Virtuel NANOBIOTIX Nanothérapeutique
PRESS RELEASE

published on 12/17/2024 at 22:15, 1 year 7 months ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix announces virtual event 'Accelerating the Future of Nanotherapeutics' on December 19, 2024, showcasing Curadigm Nanoprimer Platform for drug development

Virtual Event NANOBIOTIX Curadigm Nanotherapeutics Nanoprimer
BRIEF

published on 12/09/2024 at 22:20, 1 year 8 months ago

Nanobiotix conclut avec succès une étude de phase 1 sur le cancer du pancréas

FDA Étude De Phase 1 Cancer Du Pancréas Chimiothérapie Radiothérapie
BRIEF

published on 12/09/2024 at 22:20, 1 year 8 months ago

Nanobiotix successfully completes phase 1 study in pancreatic cancer

FDA Pancreatic Cancer Chemotherapy Phase 1 Study Radiotherapy
PRESS RELEASE

published on 12/09/2024 at 22:15, 1 year 8 months ago

NANOBIOTIX annonce l’achèvement de l’étude de phase 1 avec NBTXR3 (JNJ-1900) dans le cancer du pancréas
Nanobiotix annonce l'achèvement de l'étude de Phase 1 avec NBTXR3 dans le cancer du pancréas, avec des résultats encourageants. Un essai randomisé est prévu. Plus d'informations sur www.nanobiotix.com

Étude De Phase 1 Cancer Du Pancréas NANOBIOTIX NBTXR3 Essai Randomisé
PRESS RELEASE

published on 12/09/2024 at 22:15, 1 year 8 months ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Nanobiotix completes Phase 1 study of NBTXR3 in pancreatic cancer, showing promising outcomes & safety profile. FDA approves new trial. Full data to be shared in 2025

FDA Approval Pancreatic Cancer NANOBIOTIX NBTXR3 Phase 1 Study
BRIEF

published on 11/25/2024 at 09:53, 1 year 8 months ago

Franchissement de Seuil par Baillie Gifford chez Nanobiotix

Capital Droits De Vote Franchissement De Seuil NANOBIOTIX Baillie Gifford
BRIEF

published on 11/25/2024 at 09:53, 1 year 8 months ago

Threshold Crossing by Baillie Gifford at Nanobiotix

Voting Rights Capital Threshold Crossing NANOBIOTIX Baillie Gifford
PRESS RELEASE

published on 11/25/2024 at 09:48, 1 year 8 months ago

Franchissement de seuil
Déclaration de franchissement de seuil par Baillie Gifford & Co. pour NANOBIOTIX le 19 novembre 2024

Franchissement De Seuil NANOBIOTIX Baillie Gifford & Co.
BRIEF

published on 10/31/2024 at 08:35, 1 year 9 months ago

NANOBIOTIX to Participate in Investor Conferences in November

Innovation Investors Healthcare Conférences NANOBIOTIX

Accesswire

Published on 08/15/2026 at 00:50, 1 day 1 hour ago

Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 1 day 1 hour ago

Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 1 day 2 hours ago

AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 1 day 2 hours ago

NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 1 day 2 hours ago

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

View all ACCESSWIRE

EQS Group

Published on 08/15/2026 at 15:05, 10 hours 44 minutes ago

Brook Gaming Officially Launches Sniper 2 Flagship Keyboard and Mouse Converter for Cross-Platform Console Gaming
Published on 08/15/2026 at 08:05, 17 hours 44 minutes ago

SKYWORTH Solar to Launch SolaMate Balcony Solar System on Joybuy Germany on August 15
Published on 08/14/2026 at 18:29, 1 day 7 hours ago

Designated Persons Notifications
Published on 08/14/2026 at 18:29, 1 day 7 hours ago

Designated Persons Notifications
Published on 08/14/2026 at 18:15, 1 day 7 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 08/13/2026 at 18:00, 2 days 7 hours ago

Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 4 days 8 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 4 days 8 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 5 days 7 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 5 days 7 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

View all LES ECHOS COMFI WIRE